IMW 2019 | PROMISE: why early detection of MGUS is vital to reducing MM incidence
Irene Ghobrial, Kenneth Anderson and Robert Kyle
• 14 Sep 2019
Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, and Robert Kyle, MD, Mayo Clinic, Rochester, MN, here discuss the PROMISE study in a roundtable meeting at the International Myeloma Workshop (IMW) 2019, in Boston, MA. They highlight why detecting MGUS is crucial to reducing the instance of progression to MM, and how the PROMISE study will be influential in the future of myeloma-related screening program development.
